Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Arc's aim is to become the market leader in electrical recreational vehicles by using licensed battery automotive technology as the base. The company was born out of Jaguar Land Rover’s White Space. Since its pre-launch, the ‘Vector’ has attracted global interest with over 590 news articles covering its release across 55 countries. Arc also witnessed over 130 sales inquiries in relation to the limited 399 units which it is planning to produce. The company is on a mission of creating vehicles that challenge the environment while protecting it.
days to go:
Expired
investment:
£1,067,420
AutoTrip have automated the recording of business milage with a simple internet connected device. These devices can be self-installed and can save businesses up to 35% of their car fleet costs.
days to go:
Expired
investment:
£435,370
Skinny Tonic™ is the first Zero Calorie, Nothing Artificial, and Zero Sugar, 100 % Natural Tonic Water in the UK. It has a nationwide listing in Asda and a 2nd major listing agreed for 2020. Skinny Tonic™ also has been listed in major retailers including Amazon and Costco. The company has a bespoke, fully automated production facility capable of producing 6,000 cans per hour. With the proceeds, the company will recruit a marketing and sales team. Additionally, Skinny Tonic™ will increase its product development and production capacity.
days to go:
Expired
investment:
£1,783,994
Noveltea is a premium alcoholic tea brand launched in Fenwick in April 2017. The company's products are vegan, gluten-free and low in sugar, and manufactured in minimalistic & up-cyclable lifestyle packaging. Thanks to its low-Alcohol by volume (ABV) portfolio, the brand has sold 350,000 bottles since its launch in 2017. The company experienced more than £100,000 worth of sales in April 2020 despite COVID-19 due to smart e-commerce channel utilisation. In 2020, the size of the global alcoholic drinks market is $1.587 trillion and is forecasted to grow by 3.5% (CAGR) over the next three years. The brand aims to become a major contender in this segment and grow its business. The company use the investment to focus on its core markets in the UK, Germany, and China, and enter the USA by 2020.
days to go:
Expired
investment:
£558,845
Buzzbike is a disruptive new way for brands to advertise around the city, putting thousands of bikes on the road along the way. Each bike is fully branded which allows Buzzbikes partners to design a full fleet of bikes. To maximise impact, bikes are clustered and geo-targeted in places the brand wants to be seen by recruiting riders who work and park in those locations. Buzzbikes are completely free for the rider, all you have to do is ride to work a minimum of 12 times a month and street park. They are also giving away lock, lights, insurance and yearly servicing, as well as a discount at their kit partner Brooks.
days to go:
Expired
investment:
£388,870
Chris James Mind Body is a premium health and lifestyle brand that offers a uniquely natural solution to help you acheive optimal levels of health and wellness all year round. Chris James has also created a 12 days cleanse plan as well as signing a book deal with the British publisher Penguin.
days to go:
Expired
investment:
£60,500
